Parkinson's Disease Trial, Recruiting NCT07302386 Sponsor: Marmara University Condition: Parkinson's Disease
Back to Parkinsons Disease

Parkinson's Disease Trial, Recruiting

NCT07302386
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with Idiopathic Parkinson's Disease by a neurologist, using a specific set of recognised diagnostic guidelines (known as the UK Parkinson's Disease Association Brain Bank criteria)
  • People whose Parkinson's disease falls within stages I to III on a standard rating scale called the Hoehn and Yahr scale, which covers mild to moderate stages of the condition
  • People who score 21 or higher on a standard memory and thinking test called the Montreal Cognitive Assessment (MoCA)
  • People who have access to the necessary technology at home to take part in remote, online rehabilitation sessions
  • People who are able to walk at least 100 metres
  • People who have completed at least primary school level education

Who may not be able to join:

  • People who have a neurological condition in addition to Parkinson's disease
  • People who have a heart, lung, or joint/muscle problem that affects the way they walk or their ability to balance
  • People who are currently receiving Deep Brain Stimulation (DBS) therapy, or who have had DBS surgery at any point in the past (DBS is a treatment that involves a device implanted in the brain)
  • People who have vision or hearing difficulties

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Semra Oğuz, PhD, Marmara University

Phone: +905055624837

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Marmara University
Registry
ClinicalTrials.gov
Start date
15 December 2025
Est. completion
7 November 2026

Where this trial is recruiting

Turkey (Türkiye)

Primary endpoints

Change in motor impairment; Change in behavioral regulations in exercise; Change in lower extremity power and endurance; Change in walking speed; Change in mobility; Change in body position; Change in quality of life

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov